Pro-inflammatory cytokines in spondyloarthritis: a case-control study

References

• Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84. doi: 10.1016/S0140-6736(16)31591-4
   PubMed Web of Science ®Google Scholar
• Stolwijk C, van Onna M, Boonen A, et al. Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res (Hoboken). 2016;68(9):1320–1331. doi: 10.1002/acr.22831
   PubMed Web of Science ®Google Scholar
• Slouma M, Abbess M, Kharrat L, et al. Ultrasonography of heel entheses in axial spondyloarthritis patients: frequency and assessment of associated factors. J Ultrasound. 2023;26(1):185–192. doi: 10.1007/s40477-022-00715-x
   PubMed Web of Science ®Google Scholar
• Duba AS, Mathew SD. The seronegative spondyloarthropathies. Prim Care Clin Off Pract. 2018;45(2):271–287. doi: 10.1016/j.pop.2018.02.005
   PubMed Web of Science ®Google Scholar
• Chen B, Li J, He C, et al. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (review). Mol Med Rep. 2017;15(4):1943–1951. doi: 10.3892/mmr.2017.6248
   PubMed Web of Science ®Google Scholar
• Wendling D, Guillot X, Prati C. The IL-23/Th 17 pathway in spondyloarthritis: the royal road? Joint Bone Spine. 2015;82(1):1–4. doi: 10.1016/j.jbspin.2014.08.003
   PubMed Web of Science ®Google Scholar
• Slouma M, Rouatbi F, Ben Ammar L, et al. Effect of tumor necrosis factor inhibitors on hip involvement in ankylosing spondylitis: is structural repair possible? J Rheumatol. 2023;51(1):104–105. jrheum.2023-0446. doi: 10.3899/jrheum.2023-0446
   Web of Science ®Google Scholar
• Cachen L, Nocturne G, Collins M, et al. Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF. RMD Open. 2022;8(1):e001697. doi: 10.1136/rmdopen-2021-001697
   PubMed Web of Science ®Google Scholar
• Carriero A, Lubrano E, Picerno V, et al. Paradoxical psoriatic arthritis in a patient with psoriasis treated with guselkumab. Clin Exp Dermatol. 2022;47(4):783–785. doi: 10.1111/ced.15061
   PubMed Web of Science ®Google Scholar
• Chokshi A, Demory Beckler M, Laloo A, et al. Paradoxical tumor necrosis factor-alpha (TNF-α) inhibitor-induced psoriasis: a systematic review of pathogenesis, clinical presentation, and treatment. Cureus. 2023;15(8):e42791. doi: 10.7759/cureus.42791
   PubMed Web of Science ®Google Scholar
• Liu CH, Chou CT, Chen CH, et al. Aberrant distribution and function of plasmacytoid dendritic cells in patients with ankylosing spondylitis are associated with unfolded protein response. Kaohsiung J Med Sci. 2020;36(6):441–449. doi: 10.1002/kjm2.12184
   PubMed Web of Science ®Google Scholar
• Hanson A, Brown MA. Genetics and the causes of ankylosing spondylitis. Rheum Dis Clin North Am. 2017;43(3):401–414. doi: 10.1016/j.rdc.2017.04.006
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Maksymowych WP. The pathogenesis of ankylosing spondylitis: an update. Curr Rheumatol Rep. 2019;21(10):58.
   PubMed Web of Science ®Google Scholar
• McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019;78(9):1167–1178. doi: 10.1136/annrheumdis-2019-215356
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewe R, et al. The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheumatic Dis. 2009;68(6):777–783. doi: 10.1136/ard.2009.108233
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31. doi: 10.1136/ard.2010.133645
   PubMed Web of Science ®Google Scholar
• MacKay K, Mack C, Brophy S, et al. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum. 1998;41(12):2263–2270. doi: 10.1002/1529-0131(199812)41:12<2263::AID-ART23>3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–368. doi: 10.1002/art.1780270401
   PubMed Web of Science ®Google Scholar
• Chen D, Yuan S, Zhan Z, et al. Early-stage hip involvement in patients with ankylosing spondylitis: a Chinese study based on magnetic resonance imaging. Mod Rheumatol. 2016;26(6):933–939. doi: 10.3109/14397595.2016.1153232
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21(12):2286–2291.
   PubMed Web of Science ®Google Scholar
• Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18–24. doi: 10.1136/ard.2008.094870
   PubMed Web of Science ®Google Scholar
• Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The bath as metrology index. J Rheumatol. 1994;21(9):1694–1698.
   PubMed Web of Science ®Google Scholar
• Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol. 1994;21(12):2281–2285.
   PubMed Web of Science ®Google Scholar
• Chen WS, Chang YS, Lin KC, et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc. 2012;75(7):303–308. doi: 10.1016/j.jcma.2012.05.006
   PubMed Web of Science ®Google Scholar
• Wendling D, Cedoz JP, Racadot E, et al. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74(3):304–305. doi: 10.1016/j.jbspin.2006.11.005
   PubMed Web of Science ®Google Scholar
• Wang X, Lin Z, Wei Q, et al. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int. 2009;29(11):1343–1347. doi: 10.1007/s00296-009-0883-x
   PubMed Web of Science ®Google Scholar
• Przepiera-Będzak H, Fischer K, Brzosko M. Serum IL-6 and IL-23 levels and their correlation with angiogenic cytokines and disease activity in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome. Mediators Inflamm. 2015;2015:785705. doi: 10.1155/2015/785705
   PubMed Web of Science ®Google Scholar
• Gratacós J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-α, IL-1β and IFN-γ) in ankylosing spondylitis: a close correlation between serum il-6 and disease activity and severity. Rheumatology. 1994;33(10):927–931. doi: 10.1093/rheumatology/33.10.927
   Web of Science ®Google Scholar
• Pedersen SJ, Hetland ML, Sørensen IJ, et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol. 2010;29(11):1301–1309. doi: 10.1007/s10067-010-1528-x
   PubMed Web of Science ®Google Scholar
• Wendling D, Cedoz JP, Racadot E. Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients. Clin Rheumatol. 2009;28(2):187–190. doi: 10.1007/s10067-008-1011-0
   PubMed Web of Science ®Google Scholar
• Xueyi L, Lina C, Zhenbiao W, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy. J Clin Immunol. 2013;33(1):151–161. doi: 10.1007/s10875-012-9774-0
   PubMed Web of Science ®Google Scholar
• Melis L, Vandooren B, Kruithof E, et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis. 2010;69(3):618–623. doi: 10.1136/ard.2009.107649
   PubMed Web of Science ®Google Scholar
• Andersen T, Rasmussen TK, Hvid M, et al. Increased plasma levels of IL-21 and IL-23 in spondyloarthritis are not associated with clinical and MRI findings. Rheumatol Int. 2012;32(2):387–393. doi: 10.1007/s00296-010-1655-3
   PubMed Web of Science ®Google Scholar
• Bal A, Unlu E, Bahar G, et al. Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol. 2006;26(2):211–215. doi: 10.1007/s10067-006-0283-5
   PubMed Web of Science ®Google Scholar
• Duvallet E, Semerano L, Assier E, et al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med. 2011;43(7):503–511. doi: 10.3109/07853890.2011.577093
   PubMed Web of Science ®Google Scholar
• Colbert RA, Tran TM, Layh-Schmitt G. HLA-B27 misfolding and ankylosing spondylitis. Mol Immunol. 2014;57(1):44–51. doi: 10.1016/j.molimm.2013.07.013
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Liava C, Daoussis D, et al. Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment. World J Gastroenterol. 2019;25(18):2162–2176. doi: 10.3748/wjg.v25.i18.2162
   PubMed Web of Science ®Google Scholar
• Bixio R, Bertelle D, Bertoldo E, et al. The potential pathogenic role of gut microbiota in rheumatic diseases: a human-centred narrative review. Intern Emerg Med. Published online Dec 23, 2023. doi: 10.1007/s11739-023-03496-1
   Web of Science ®Google Scholar
• Radić M, Đogaš H, Kolak E, et al. Vitamin D in psoriatic arthritis - a systematic review and meta-analysis. Semin Arthritis Rheum. 2023;60:152200. doi: 10.1016/j.semarthrit.2023.152200
   PubMed Web of Science ®Google Scholar
• Murdaca G, Greco M, Tonacci A, et al. IL-33/IL-31 axis in immune-mediated and allergic diseases. Int J Mol Sci. 2019;20(23):5856. doi: 10.3390/ijms20235856
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gerosa A, Paladin F, et al. Vitamin D and microbiota: is there a link with allergies? Int J Mol Sci. 2021;22(8):4288. doi: 10.3390/ijms22084288
   PubMed Web of Science ®Google Scholar
• Di Salvo E, Ventura-Spagnolo E, Casciaro M, et al. IL-33/IL-31 axis: a potential inflammatory pathway. Mediators Inflamm. 2018;2018:3858032. doi: 10.1155/2018/3858032
   PubMed Web of Science ®Google Scholar
• Bautista-Herrera LA, De la Cruz-Mosso U, Román-Fernández IV, et al. A potential inflammatory role of IL-31 in psoriatic arthritis: a correlation with Th17 cytokine profile. Int J Immunopathol Pharmacol. 2020;34:2058738420907186. doi: 10.1177/2058738420907186
   Web of Science ®Google Scholar
• Rosine N, Etcheto A, Hendel-Chavez H, et al. Increase in il-31 serum levels is associated with reduced structural damage in early axial spondyloarthritis. Sci Rep. 2018;8(1):7731. doi: 10.1038/s41598-018-25722-z
   PubMedGoogle Scholar
• Navarro-Compán V, Puig L, Vidal S, et al. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Front Immunol. 2023;14:1191782. doi: 10.3389/fimmu.2023.1191782
   PubMed Web of Science ®Google Scholar
• Taams LS, Steel KJA, Srenathan U, et al. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14(8):453–466. doi: 10.1038/s41584-018-0044-2
   PubMed Web of Science ®Google Scholar
• Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol. 2014;26(4):361–370. doi: 10.1097/BOR.0000000000000069
   PubMed Web of Science ®Google Scholar
• Limón-Camacho L, Vargas-Rojas MI, Vázquez-Mellado J, et al. In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis. J Rheumatol. 2012;39(4):830–835. doi: 10.3899/jrheum.110862
   PubMed Web of Science ®Google Scholar
• Rabelo C, Baptista TSA, Petersen LE, et al. Serum IL-6 correlates with axial mobility index (bath ankylosing spondylitis metrology index) in Brazilian patients with ankylosing spondylitis. Open Access Rheumatol. 2018;10:21–25. doi: 10.2147/OARRR.S130176
   PubMed Web of Science ®Google Scholar
• Liu C, Chu D, Kalantar-Zadeh K, et al. Cytokines: From Clinical Significance to Quantification. Adv Sci. 2021;8(15):e2004433. doi: 10.1002/advs.202004433
   Web of Science ®Google Scholar
• Holt I, Cooper RG, Hopkins SJ. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest. 1991;21(5):479–484. doi: 10.1111/j.1365-2362.1991.tb01398.x
   PubMed Web of Science ®Google Scholar
• Inman RD, Baraliakos X, Hermann KGA, et al. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. Arthritis Res Ther. 2016;18(1):304. doi: 10.1186/s13075-016-1200-1
   PubMedGoogle Scholar
• Azevedo VF, Faria-Neto JR, Stinghen A, et al. IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents. Rheumatol Int. 2013;33(7):1779–1783. doi: 10.1007/s00296-012-2631-x
   PubMed Web of Science ®Google Scholar
• Vazquez-Del Mercado M, Garcia-Gonzalez A, Muñoz-Valle JF, et al. Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol. 2002;29(3):522–526.
   PubMed Web of Science ®Google Scholar
• Grygiel-Górniak B, Puszczewicz M. Fatigue and interleukin-6 - a multi-faceted relationship. Reumatologia. 2015;53(4):207–212. doi: 10.5114/reum.2015.53998
   PubMedGoogle Scholar
• Maksymowych WP. Spondyloarthritis in 2012: advances in pathogenesis through animal models and imaging. Nat Rev Rheumatol. 2013;9(2):72–74. doi: 10.1038/nrrheum.2012.233
   PubMed Web of Science ®Google Scholar
• Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999;42(5):963–970. doi: 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E
   PubMedGoogle Scholar
• Ruiz de Morales JMG, Puig L, Daudén E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmunity Reviews. 2020;19(1):102429. doi: 10.1016/j.autrev.2019.102429
   PubMed Web of Science ®Google Scholar
• Guedes MCE, Borrego LM, Proença RD. Roles of interleukin-17 in uveitis. Indian J Ophthalmol. 2016;64(9):628–634. doi: 10.4103/0301-4738.194339
   PubMed Web of Science ®Google Scholar
• Hysa E, Cutolo CA, Gotelli E, et al. Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: an update. Eur J Clin Invest. 2021;51(8):e13572. doi: 10.1111/eci.13572
   PubMed Web of Science ®Google Scholar
• Tagirasa R, Kaza H, Basu S. Increased local expression of P-glycoprotein on CD4+ T-cells in vitreous of patients with non-infectious uveitis: a pilot study. Ophthalmic Res. [Published online Oct 28, 2020]. doi: 10.1159/000512619
   Google Scholar
• Benham H, Norris P, Goodall J, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther. 2013;15(5):R136. doi: 10.1186/ar4317
   PubMed Web of Science ®Google Scholar
• Østergaard M. MRI of the sacroiliac joints: what is and what is not sacroiliitis? Curr Opin Rheumatol. 2020;32(4):357–364. doi: 10.1097/BOR.0000000000000718
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: new advances in diagnosis and management. BMJ. 2021;372:m4447. doi: 10.1136/bmj.m4447
   PubMed Web of Science ®Google Scholar
• El Mansouri L, Bahiri R, Abourazzak FE, et al. Two distinct patterns of ankylosing spondylitis in Moroccan patients. Rheumatol Int. 2009;29(12):1423–1429. doi: 10.1007/s00296-009-0873-z
   PubMed Web of Science ®Google Scholar
• Costantino F, Talpin A, Said-Nahal R, et al. Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort. Ann Rheum Dis. 2015;74(4):689–693. doi: 10.1136/annrheumdis-2013-204436
   PubMed Web of Science ®Google Scholar
• Dinneen B, O’Shea F, Gensler L. Structural disease modification in axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2023;37(3):101898. doi: 10.1016/j.berh.2023.101898
   PubMed Web of Science ®Google Scholar
• Nakamura A, Towheed T. Pathogenesis, assessment, and management of bone loss in axial spondyloarthritis. Semin Arthritis Rheum. 2023;64:152345. doi: 10.1016/j.semarthrit.2023.152345
   PubMed Web of Science ®Google Scholar